Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
SELLAS Life Sciences Group (SLS) is drawing fresh attention as investors reassess immune based cancer therapy stocks following Moderna and Merck’s Phase 3 cancer vaccine update and the broader oncology rally it helped spark.
See our latest analysis for SELLAS Life Sciences Group.
At a latest share price of $13.40, SELLAS Life Sciences Group has seen a 72.24% 90 day share price return and a very large 1 year total shareholder return. This suggests momentum has been building as attention shifts to immune based cancer therapies rather than its recent earnings loss.
If Moderna and Merck’s cancer vaccine update has you looking beyond a single stock, this is a useful moment to scan other immune focused names through our healthcare AI stock screener, starting with 40 healthcare AI stocks.
For SELLAS Life Sciences Group, the sharp move and very large 1 year return sit against a business that still reports losses and no revenue. Is this mainly a reset in sentiment, or a fair reflection of value as it stands today?
Preferred Price to Book Multiple of 19.7x: Is it justified?
On simple valuation grounds, SELLAS Life Sciences Group looks expensive at a P/B of 19.7x compared with both its biotech peers and the wider market, especially given the company currently reports losses and no revenue.
The price to book ratio compares the market value of a company to its net assets on the balance sheet. For a business like SELLAS Life Sciences Group, which is still in the clinic with no commercial revenue, this multiple effectively reflects what investors are willing to pay today for the company’s pipeline, partnerships and future cash flow potential rather than current earnings power.
That premium is clear when set beside references in the data. SLS is described as expensive versus a peer average P/B of 14.1x and also expensive versus the broader US Biotechs industry average of just 2.5x. This suggests the market is pricing in a high level of expectation for future progress relative to asset value, rather than treating the stock as a balance sheet play.
Given that context, the recent very strong share price performance, the absence of current revenue, and the P/B premium all point to a market that is paying up for potential rather than present day fundamentals. For anyone looking at the stock, the key question is whether that gap to peers feels justified by the company’s pipeline, partnerships and forecast growth profile.
Leave a comment